Opportunities include the rising demand for innovative biologics and the increased need for diverse cell lines, including ...

The host cell system is a critical determinant of recombinant protein quality and yield, with direct influence on protein folding and post-translational modification factors that shape the ...

The cell line development market is driven by rising biologics production, increasing demand for monoclonal antibodies, and advancements in expression systems, with North America leading and ...

Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced a licensing agreement for its CHO Edge System with RevOpsis Therapeutics ("RevOpsis"), a ...

Validated across diverse cell lines and molecule formats, switching to UltraFeed as the fed-batch supplement has enabled titers reaching 10g/L, with peak VCD increases up to 20% and harvest viability ...

Discover how to streamline your cell line development process for recombinant protein and monoclonal antibody production with this in-depth eBook. Whether you're working with CHO, HEK293, or hybridoma ...

BOSTON, March 17, 2026 (GLOBE NEWSWIRE) -- Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced a cell line development partnership with Score ...

Chinese hamster ovary (CHO) cell lines are one of the most-used cell-based protein expression systems for therapeutics, thanks to their ability to support post-translational modifications such as ...

SHANGHAI, Aug. 11, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of WuXia293 Stable ...